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Objective: The aim of this study was to assess the pulmonary function of children with 
acute leukemia. 
Methods: Cross-sectional observational analytical study that enrolled 34 children divided 
into groups A (17 with acute leukemia in the maintenance phase of chemotherapy) and B 
(17 healthy children). The groups were matched for sex, age and height. Spirometry was 
measured using a spirometer Microloop Viasys® in accordance with American Thoracic 
Society and European Respiratory Society guidelines. Maximal respiratory pressures 
were measured with an MVD300 digital manometer (Globalmed®). Maximal inspiratory 
pressures and maximal expiratory pressures were measured from residual volume and 
total lung capacity, respectively. 
Results: Group A showed a significant decrease in maximal inspiratory pressures when 
compared to group B. No significant difference was found between the spirometric 
values of the two groups, nor was there any difference between maximal inspiratory 
pressure and maximal expiratory pressure values in group A compared to the lower limit 
values proposed as reference.
Conclusion: Children with acute leukemia, myeloid or lymphoid, during the maintenance 
phase of chemotherapy exhibited unchanged spirometric variables and maximal expiratory 
pressure; However, there was a decrease in inspiratory muscle strength.
© 2014 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
☆Study conducted at Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
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Introduction
Leukemia, a malignant disease most frequently found in 
patients aged from 0 to 18 years old, represents 25-35% of all 
tumors in this population.1 Leukemia almost always presents 
in its acute form in children. Leukemia is classified according 
to cytology, immunohistochemistry and cytogenetics as acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia 
(AML).2 ALL represents 70-80% of the cases and AML represents 
approximately 15% of the cases.3
The chosen treatment for this neoplasia is chemotherapy, 
which can be used in conjunction with other therapies. The 
chemotherapy protocols last more than a year and a half.4 
The treatment is divided into phases with the maintenance 
phase being the lengthiest period of the treatment. It is also 
the stage in which children already have greater clinical 
stability and have passed through the other stages.4
In the last four decades, continuous improvements in 
treatment results have been observed in children with 
this neoplasia. Due to enhanced prognosis, there is a 
need to consider the morbidity induced by treatment 
protocols. Studies report the following complications: 
secondary leukemia and complications in musculoskeletal, 
pulmonary, urinary, gastrointestinal, cardiac and nervous 
systems.5 
Children treated for cancer face the risk of complications 
including pulmonary dysfunction.6 Pulmonary toxicity due 
to the chemotherapy or associated with radiotherapy may 
also result in interstitial lung injury during an initial stage 
until several months after the treatment and, in a late 
stage, the most common problem is lung fibrosis.7 
It has been demonstrated that the use of high doses of 
cyclophosphamide, arabinosil cytosine, anthracyclines, 
dexamethasone and 6- thioguanine, medications used in the 
treatment of leukemia, as well as their combination, may 
lead to pulmonary toxicity and predispose to infections.8,9 
High-doses of anthracycline may affect lung function 
causing congestive heart failure.8 Use of higher doses of 
arabinosil cytosine, anthracyclines, and cyclophosphamide 
intravenously have been associated with reduced lung 
volumes and capacities.8 Chemotherapy-induced lung 
fibrosis in children can remain asymptomatic for many 
years and may become symptomatic at any time.9 
Studies report that the pulmonary function of individuals 
with leukemia may be altered8,10; however, it is not 
known whether these alterations are already present 
during chemotherapy or only at long-term. The role of 
physiotherapy in these patients is necessary to minimize 
the adverse effects of treatments. Accordingly, this study 
aimed at assessing the pulmonary function of children 
with acute leukemia during the maintenance phase of 
chemotherapy treatment and, thus, to identify whether 
the pulmonary function is already altered during the acute 
phase of the treatment. 
Method
This cross-sectional observational analytical study was 
approved by the Research Ethics Committee of the Federal 
University of Rio Grande do Norte (no. 273/2008) and the 
LIGA Norte Riograndense Contra o Câncer (no. 185/185/2010 
Função pulmonar de crianças com leucemia aguda na fase de manutenção da quimio-
terapia 
Resumo 
Objetivo: O objetivo desse estudo foi avaliar a função pulmonar de crianças com leu-
cemia aguda. 
Métodos: Trata-se de um estudo observacional do tipo analítico transversal com 34 crian-
ças, divididas nos grupos A (17 crianças com leucemia aguda na fase de manutenção do 
tratamento quimioterápico) e B (17 crianças saudáveis). Os grupos foram pareados em 
relação ao sexo, idade e altura. A espirometria foi mensurada utilizando um espirôme-
tro Microloop Viasys®, de acordo com as recomendações da American Thoracic Society 
e European Respiratory Society. As pressões respiratórias máximas foram mensuradas 
utilizando um manovacuômetro digital MVD300 (Globalmed®). As pressões inspiratória 
máxima e expiratória máxima foram mensuradas a partir do volume residual e da capa-
cidade pulmonar total, respectivamente. 
Resultados: O grupo A apresentou diminuição significativa da pressão inspiratória máxi-
ma quando comparado ao grupo B. Não foram observadas diferenças entre os dados espi-
rométricos dos dois grupos avaliados, bem como entre os valores de pressão inspiratória 
máxima e pressão expiratória máxima do grupo A com os limites inferiores propostos 
como referência. 
Conclusão: As crianças com leucemia aguda, linfoide ou mieloide não apresentam mudan-
ça das variáveis espirométricas e da pressão expiratória máxima durante o período de 
manutenção do tratamento quimioterápico; no entanto, há uma diminuição da pressão 
inspiratória máxima. 
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and 086/086/2011). Research was in accordance with the 
Declaration of Helsinki criteria.
The sample was composed of children aged between 
5 and 12 years, diagnosed with acute leukemia and in 
the maintenance phase of chemotherapy treatment at 3 
centers for childhood cancer in Rio Grande do Norte state, 
Northeast Brazil, (group A), as well as healthy school 
children, matched with group A for sex, age and height 
(group B). They were considered healthy when they did not 
have history of leukemia and/or acute or chronic diseases 
of the respiratory system. The criteria for assessment and 
classification in groups A and B are described below. 
To be included in the study, children could not display 
any of the following: diagnosis of cardiovascular or 
neuromuscular disease; diagnosis of chronic pulmonary 
disease on the standardized American Thoracic Society 
(ATS) and Division of Lung Diseases questionnaires ATS-DLD-
78-C;11 respiratory infection in the previous two weeks,12 
nausea or vomiting; thoracic deformity13 or recent thoracic 
or abdominal surgery13; hemoptysis, pneumothorax, 
cardiocirculatory instability13; pulmonary thromboembolism, 
cerebral, thoracic or abdominal aneurisms;13 recent 
upper airway, thoracic or abdominal trauma;13 acute 
middle ear problems;13 abdominal hernia;13 glaucoma, 
retinal detachment13 or recent eye surgery;13 neurological 
impairment,12,13 use of medication such as bronchodilators, 
anticholinergics, antihistamines and antileukotrienes.12
Participants who were unable to perform or understand 
any of the procedures were excluded, as well as those that: 
abandoned the study; had an acute respiratory tract disease 
during data collection; had been hospitalized for treatment; 
or missed classes or appointments at the outpatient facility 
during the assessment period.
Twenty-five children were treated at the above mentioned 
hospitals between January and September, 2011. Parents 
or legal guardians were informed about the study and gave 
their written consent. The parents of children of group 
B received an envelope containing the documentation 
required to take part in the study. In addition to parental 
consent, children participated only if they agreed to do 
so. A booklet containing appropriate language for the 
children’s age range was used to inform them about the 
experiment.
All patients underwent initial assessment, which involved 
collecting personal, spirometric and maximal respiratory 
pressures data. Peripheral oxygen saturation, blood pressure 
and heart rate were monitored during evaluations. 
Spirometry was conducted using an MK8 Microloop Viasys 
portable digital spirometer (Cardinal Health U.K. 232 LTD). 
The device follows ATS and European Respiratory Society 
guidelines.14 The equipment was manually calibrated on 
a daily basis using a 3-liter syringe to ensure accuracy. A 
disposable mouthpiece and bactericidal filter were coupled 
to the spirometer. Spirometric measurements of the children 
were conducted according to ATS and European Respiratory 
Society norms for preschool children,15 for children 5 and 
6 years old, and for those between the ages of 7 and 12.14 
During the test all participants remained seated, using the 
nasal clip and with their heads in the neutral position. 
The children were instructed to breathe in as deeply as 
possible, pause for 1 to 2 seconds and then breathe out 
with maximum effort, continuing to exhale until the end 
of the test.14 Furthermore, maneuvers had to be free of 
coughing, air leaks, mouthpiece obstruction, valsalva 
maneuver, glottal closing, hesitation or new inspiration.
Children between the ages of 7 and 12 years had to exhibit 
a volume-time curve that showed no change in volume 
greater than or equal to 0.025l during the last second 
(plateau); satisfactory test time (in general 3 seconds in 
children up to 10 years old and 6 seconds in children older 
than 10). To ensure that forced expiratory volume in the 
first second (FEV1) was performed on a maximum effort 
curve, retro-extrapolated volume had to be 5% of forced 
vital capacity (FVC) or 0.150l, whichever was higher. At 
least 3 and at most 8 maneuvers were performed to obtain 
3 acceptable ones (using the aforementioned criteria), 
with maximum difference of 0.150L (for FVC values above 
1 liter) or 0.1L (for FVC values below 1 liter) between the 
two highest. The largest measures from the two tests were 
selected.14
The 5 and 6 years old were required to perform the 
following: flow-volume curves that showed a rapid 
increase up to peak flow; retro-extrapolated volume less 
than or equal to 80ml or less than 12.5% of FVC; at least 
3 maneuvers, but with no maximum number; at least 2 
acceptable maneuvers, in which the two highest FEV1 and 
FVC could not differ by more than 0.1L or 10%.15
A 1-minute rest period was given between each 
maneuver and subjects were provided with visual and 
verbal encouragement during assessment. Flow-volume and 
volume-time curves, performed at maximum effort, were 
analyzed after each maneuver. 
FEV1, FVC and peak expiratory flow values that could 
be extracted from different curves were selected from 
acceptable and reproducible curves, and the forced 
expiratory flow value between 25% and 75% of FVC (FEF25-
75%) was selected from the curve with the highest sum of 
FVC and FEV1.
14
Respiratory muscle strength was performed 10 minutes 
after spirometry. Maximal inspiratory pressure (MIP) 
and maximal expiratory pressure (MEP) were measured 
according to the method proposed by Souza,13 using an 
MVD300 digital manometer (Globalmed®, Porto Alegre – RS, 
Brazil), calibrated between -300 and +300 cmH2O, sensitive 
to each one-centimeter variation in water. The device was 
connected to a disposable biological filter, which was coupled 
to a flat rigid mouthpiece. The manometer was connected 
to a laptop that provided visual feedback. Participants also 
received verbal feedback during maneuvers. 
To measure MIP, subjects were instructed to breathe at 
tidal volume during three consecutive respiratory cycles 
and after the examiner`s command performed maximum 
expiration (approximately up to residual volume). They were 
then asked to execute maximum inspiration approximately 
up to total lung capacity.
Similar instructions were given to evaluate MEP, differing 
in that individuals first performed maximum inspiration, 
followed by maximum expiration. During this measurement, 
the examiner supported the participants` cheeks to ensure 
minimum loss of respiratory pressure due to complacency 
of the oral cavity.16 At most, 9 maneuvers were carried out 
for each maximal respiratory pressure,17 where at least 
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three were acceptable (without air leaks and lasting at 
least 2 seconds) and 2 reproducible ones were performed 
(with values that did not differ by more than 10% of the 
highest value), the highest of which was used. Since the 
last measure could not be the highest, another one was 
taken if this occurred. 
A 1-minute rest period was given between each maneuver 
and 5 minutes between measurements of MIP and MEP. 
Children remained seated and wore a nasal clip during the 
entire test.
Since the manometer used produces a direct measure 
of peak pressure, sustained pressure was determined by 
analyzing the pressure versus time curve provided by 
the manometer software. Values were exported to the 
Microsoft Office Excel program and analyzed according to 
the protocol proposed by Borja.18
Statistical analysis was conducted with Statistical 
Package for the Social Science (SPSS) 17.0 software at a 
5% significance level. The Shapiro-Wilk test was applied to 
verify data normality. Descriptive analysis was performed 
using means and standard deviations. 
The non-paired student`s t-test was used to compare 
variables between groups A and B. Considering that 
study power is defined as the capacity to demonstrate a 
statistically significant difference (or “effect”), the effect 
size was determined from Cohen’s d calculation19 for 
comparisons between group A and B children.
Results
Among the 25 children on the maintenance phase of 
chemotherapy, 6 were ineligible to take part in the study 
(3 had Down syndrome, 1 showed an enlarged heart 
(cardiomegaly) and 2 did not have parental consent). 
The 19 remaining children were assigned to group A. Two 
of them did not understand the examiner`s command. 
Concerning the leukemia, 88.2% of participants showed 
ALL and 11.8% AML. Group B was composed of 17 healthy 
school children matched with group A patients. Therefore, 
the final study sample consisted of 34 children, 24 boys 
and 10 girls (mean age of 6.83 ± 1.4 years and 6.2 ± 1.0 
years, respectively).
The analysis of the anthropometric variables of group 
A and B subjects did not show significant difference 
between groups concerning the weight (p=0.60), height 
(p=0.88) and body mass index (p=0.44). Table 1 shows a 
comparative analysis of measures obtained by spirometry 
and manometry.
The values for maximal respiratory pressures obtained 
among 7 years old and older children from group A were 
compared with the normal lower limits proposed by 
Borja.18 No significant difference was recorded on MIP and 
MEP values between group A and those proposed by Borja18 
(p=0.96 and p=0.58, respectively).
Table 2 classifies the relative size of the statistical power 
of the study using Cohen’s d calculation.19
Discussion
The assessment of pulmonary function in children with 
acute leukemia demonstrates that spirometric and MEP 
variables of the study sample are within the expected 
for healthy controls. By contrast, the MIP is decreased. 
We found no studies considering the immediate effects 
of chemotherapy on the pulmonary function of children 
with leukemia. Most studies reached a consensus regarding 
the delayed effects of chemotherapy on the spirometry of 
leukemia survivors.6,8,10
A group of authors10 has recently performed spirometric 
tests in 42 children with hematological oncology diseases, 
Table 1 Spirometric variables and maximal respiratory pressures obtained in groups A and B; values of the mean, standard 
deviation, effect size and significance level.
Variables Group A (n=17) Group B (n=17) p-value Relative Size
FEV1 (L) 1,16±0,26 1,34±0,29 0,060 
FVC (L) 1,23±0,30 1,45±0,35 0,056 
FEV1/FVC 94,12±5,60 93,24±7,03 0,688 
FEF25-75% (L/s) 1,71±0,53 1,73±0,48 0,928 
PFE (L/s) 2,69±0,74 3,00±0,84 0,254 
MIP(cmH2O) 44,71±11,80 63,82±17,75 0,000
a 1,31
MEP (cmH2O) 62,76±19,03 67,82±15,28 0,399 
ap<0,05. FEV1, Forced Expiratory Volume in the First Second; FVC, Forced Vital Capacity; FEV1/FVC, Ratio of forced expiratory volume 
in the first second and forced vital capacity; FEF25-75%, Forced Expiratory Flow Value Between 25% and 75% of FVC; PEF, Peak Expiratory 
Flow; MIP, Maximal Inspiratory Pressure; MEP, Maximal Expiratory Pressure
Table 2 Classification of the relative size of the statistical 
power of the study using Cohen’s d calculation19.
Relative Size of Cohen’s d
Negligible effect (≥-0.15 e <.15)
Small effect (≥.15 e <.40)
Medium effect (≥.40 e <.75)
Large effect (≥.75 e <1.10)
Very Large effect (≥1.10 e <1.45)
Huge effect >1.45
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comparing data with healthy children. The authors reported 
that 19% of the children with cancer revealed severely 
limited air flow before treatment. They also observed 
that three years after the clinical treatment, half of these 
children recovered normal pulmonary function while the 
remainder exhibited a worsened pattern. Finally, of the 42 
children assessed, 38 showeda lightly impaired air flow in 
the long term.
Other studies also showed consistent results regarding 
delayed impairment in spirometric variables after diagnosis 
of leukemia in childhood.8,20 In the first study,8 the authors 
performed spirometry in patients with acute lymphoid 
leukemia in childhood which were treated with different 
chemotherapy and radiotherapy protocols. After eight 
years, 61% of the sample had normal pulmonary function. 
Reduced pulmonary function was related to the young age 
and the use of more intensive protocols. In the second 
study,20 the researchers made a comparative analysis of 
three patient groups (chemotherapy, chemotherapy and 
radiotherapy and chemotherapy, radiotherapy and bone 
marrow transplant groups) 10 years after their acute 
myeloid leukemia treatment and observed that 20% of the 
patients treated with chemotherapy, radiotherapy and 
bone marrow transplant presented mild restrictive lung 
disorder.
Researchers from Egypt6 performed pulmonary tests in 
children who survived leukemia and lymphoma, observing 
that 25% of those treated with chemotherapy alone had 
pulmonary dysfunction. This percentage was higher than 
70% among those who also required radiotherapy.
These studies show that deteriorated pulmonary function 
in patients with hematological cancer seems to be strongly 
related to more aggressive chemotherapy protocols and the 
addition of radiation and/or bone marrow transplant. From 
the present study, Group A, composed of children with 
acute leukemia on the maintenance phase of chemotherapy, 
did not undergo radiotherapy or bone marrow transplant, 
in addition to chemotherapy.This aspect, supported by 
the lack of scientific evidence of immediate spirometric 
alterations following chemotherapy alone, seems to justify 
the our findings. Therefore, during the maintenance 
phase of chemotherapy, children do not seem to present 
significant decrease in lung volumes and capacities when 
compared to healthy controls.
Loss of respiratory muscle strength can occur before 
reduced pulmonary function is detected, as seen in 
neuromuscular disorders.21 Macedo et al22 assessed the 
maximal respiratory pressures of 14 children with acute 
leukemia and observed a decrease in MIP and in MEP 
in most children, according to normal values proposed 
by Wilson et al23. Oliveira et al24 assessed the MIP and 
MEP of children with acute leukemia, comparing them 
with measures obtained in healthy controls and found 
a significant reduction in MIP in children with acute 
leukemia, as shown in the present study. The lower limit 
of normal for maximal respiratory pressures has been 
used to confirm if a patient is suffering from respiratory 
muscle weakness.25 If the value obtained for maximal 
respiratory pressures is less than the lower limit of normal 
proposed, the chance of respiratory muscle weakness is 
95%.25 Despite the significant reduction in MIP in group A 
children from the present study, this variable was higher 
than the lower limit of normal recently proposed for 
the studied age range.18 These findings suggest that the 
chance of these children being definitively diagnosed with 
inspiratory muscle weakness is at most 5%.
The study has its limitations. The wide divergence 
concerning treatment protocols used in earlier studies and 
the difficulty on finding pulmonary function data during 
the acute phase of chemotherapy treatment limited the 
discussion of our findings. A further limitation is the absence 
of more accurate information on the physical activity levels 
of the participating children. Moreover, the impossibility to 
analyze the pulmonary function of children with the two 
studied types of leukemia sepatately, as well as non-precise 
description of the medication and its dosage used in the 
leukemia treatment impair a more detailed discussion of 
the findings. 
Currently, the evaluation of lung function is not yet part 
of the routine monitoring of outpatients with blood cancers. 
Although the literature indicates an improvement in survival 
of children with leukemia subjected to more advanced 
treatment protocols, there is still little information about 
respiratory evaluation of these patients.5 Thus, this pioneer 
study may add information about the lung function effects 
of these treatments in children with acute leukemia. The 
identification of these effects may guide a best physical 
therapy care to these children.
Finally, the spirometric variables of children with 
acute leukemia did not change during the chemotherapy 
maintenance phase. Although MEP of children with leukemia 
did not differ significantly from that of the healthy controls, 
MIP declined in this population. As a result, physiotherapy 
could be performed in an attempt to preserve muscle 
strength, minimizing consequent effects of respiratory 
muscle weakness which could have an effect on quality of 
life in children with cancer.
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